

BSW Formulary Update – January 2022

New and Updated Shared Care Agreements and Prescribing Guidance

- **Updated** – [Management of Infection: Guidance for Primary Care](#)
Update includes information on treating infected laceration wounds in line with [CKS topic](#).
- **Updated** – [Actinic \(solar\) Keratoses: Guidelines for Management](#)
Update includes tirbanibulin ointment as a 2nd/3rd line option for small lesions of face/scalp.

New additions to BSWformulary

- [Melatonin for insomnia in Parkinson's Disease](#)
The use of melatonin for insomnia in patients with Parkinson's disease with significant sleep-wake cycle disturbance refractory to non-pharmacological methods or to controlled-release L-dopa taken at night has been approved. This indication has currently been assigned with **RED TLS** but remains under review with a view to move to AMBER.
- A note has been added to the [Bempedoic acid entry](#)
The use of Bempedoic acid as monotherapy is within its product license but outside of current NICE recommendations. In patients with true intolerance to ezetimibe, the use of bempedoic acid as monotherapy is ONLY supported locally after initiation by a Lipid Specialist and where there are no other suitable alternative treatment options. Transfer for the responsibility of prescribing to primary care can be considered following review of treatment efficacy by the Lipid Specialist. Monotherapy is therefore considered to be an **AMBER TLS** indication.
- Information on use of Goserelin Acetate (Zoladex[®]/Zoladex LA[®]) and Leuprorelin Acetate (Prostap 3 DCS[®]/Prostap SR DCS[®]) for breast cancer has been added to the existing entries in [Chapter 08.03.04.02](#). Use is approved within product licence with **AMBER TLS**.
- [Paxlovid 150 mg/100 mg film-coated tablets](#) – added with **RED TLS** for use in line with NHS commissioning policy and according to Trust procedures.
- [Delstrigo 100mg/300mg/245mg film coated tablets](#) - added with **RED TLS** for HIV as per NHSE commissioning policy.

Aligned on BSWformulary

- [Methyl-5-aminolevulinate \(Metvix[®]\) 160mg/g cream](#) – aligned with **RED TLS**

Other BSWformulary website updates

- The MHRA PAR for [Chloramphenicol eye drops containing borax and boric acid buffers: review of the use in children under 2 years](#) has been added to the paediatric entry [here](#). The review concludes that the benefits outweigh the risks of using chloramphenicol eye drops containing borax and boric acid when indicated for children aged 0 to 2 years
- [Dessicated \(natural\) thyroid extract products](#) – added key words and link to new SPS [evidence review](#) to reinforce **non-formulary status**.
- Ephedrine nasal drops 0.5% and 1% - removed from formulary as products discontinued

What the BSW CCG formulary team are currently working on

- Working with the BSWCCG Medicines Optimisation Team to review Optimise Profiles in line with BSWformulary. *Please contact bswccg.prescribing@nhs.net in the first instance to clarify TLS status if you have prescribing queries.*
- Updating local SCAs. Currently several versions of some SCAs exist reflecting on the previous separate CCGs, we continue to work to align as one version for BSW.
- Updating the BSW Plaque psoriasis pathway with bimekizumab in line with NICE TA723.
- Updating the BSW HRT pathway.
- Reviewing the formulary position of medical devices that generate frequent prescribing enquiries from primary care.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net